Alluvi, formerly BI 4744, presents a notable advance in weight loss therapy. This dual agonist targeting both GLP-1 and GIP targets demonstrates impressive effectiveness in clinical assessments, potentially surpassing https://alluvi030830.bloggerchest.com/profile